At a webinar hosted by the federal Substances and Mental Health Services Administration (SAMHSA) last week, a leading cannabis researcher threw cold water on the notion that legalizing marijuana leads to increases in youth use of the drug. He also touched on problems with roadside assessments of cannabis impairment, the risk of testing positive for THC after using CBD products and the need for more nuanced regulation around cannabinoids themselves.
The public talk, from Ryan Vandry, an experimental psychologist and professor at Johns Hopkins University’s Behavioral Pharmacology Research Unit, was aimed at providing continuing education on marijuana for healthcare professionals. Titled “Behavioral Pharmacology of Cannabis – Trends in Use, Novel Products, and Impact,” it focused primarily on how variables like dosage, product formulation, mode of administration and chemical components such as terpenes can influence the drug’s effects.
Vandry began by noting that marijuana is the most commonly used illicit drug in the United States. While self-reported consumption by adults has risen as more states have legalized in recent years, he noted, use by youth has generally remained flat or fallen.
“Use among youth is one of the biggest areas of concern related to the legalization and increased accessibility of cannabis,” he said, “but surprisingly, that cohort has actually maintained relatively stable [for] both past-year and daily use.”
Pointing to data from California going back to 1996, when the state ended prohibition for medical patients, Vandry said there has “really been no change in the rates of cannabis use among eighth, 10th or 12th graders. And in fact, in very recent years, we’ve seen a decrease in rates of consumption.”
The researcher repeatedly emphasized the need for policymakers and health experts to differentiate between different kinds of cannabis, focusing less on delta-9 THC levels—which currently distinguish hemp from marijuana at the federal level—and more on a given product’s physical and cognitive impacts.
“There is a gap between our understanding of these products and the evolution of retail cannabis products,” Vandry said. “The cannabis industry is driving diversity through competition, and scientifically, we’re having a hard time keeping up with the diversity of products that are coming out.”
In general, he called for differentiating between THC-dominant products, CBD dominant products and other cannabinoid products based on their behavioral and health effects. THC and similar cannabinoids—including delta-8 THC, which is usually derived from legal hemp—exhibit characteristics typical of drugs of abuse, Vandry said, such as substance use disorders, withdrawal and impairment.
“CBD is a very different animal,” he continued, noting that research shows “no evidence” of impairment or problem use, even when administered alongside very small amounts of THC. Another cannabinoid, CBG, “looks surprisingly similar to CBD in that it really doesn’t produce THC-like effects,” he said, citing a colleague’s research.
But Vandry pointed to the current legal distinction between delta-8 THC and delta-9 THC—which both cause psychoactive effects—as an example of where regulations lag behind cannabis science. While delta-8 is metabolized more quickly in the body and is often described as less potent, a study he was involved in “showed…that if you just take double the dose of delta-8, you can get the exact same effects as delta-9,” he said.
“But again, these two chemicals exist in extremely different areas in terms of federal policy and regulation,” the researcher continued. “Delta-9 THC is a Schedule I drug, and delta-8 THC is completely unscheduled if derived from hemp.”
Another area where current policies are inadequate is evaluating marijuana-related impairment. Vandry and colleagues looked at three standard field sobriety tests used by law enforcement and found that even people who were administered THC and showed signs of impaired psychomotor ability could pass the common screening tests.
Subjects given a 25 milligram dose of THC, meanwhile, which Vandry said caused observable impairment, often tested below per se THC blood limits, especially when the cannabinoid was taken orally.
“Blood levels and blood concentrations of THC after oral ingestion are very low compared to the peak levels with inhalation, despite relatively equal pharmacodynamic effects,” he explained. In one experiment, people given 25 mg of THC registered a peak concentration of only two nanograms THC per milliliter of blood, “which, in some areas, is less than the per se cutoff for detection of impairment.”
People who combined alcohol and marijuana also showed significant impairment even when neither their blood alcohol nor THC levels rose above per se limits.
“This is a public health issue that we need to work to resolve and figure out,” Vandry said.
While roadside tests could in some cases be missing signs of impairment, other tests might incorrectly lead to false positives.
For example, many CBD products contain very small amounts of THC. Vandry said that in research, people who took similar products sometimes ended up testing positive for the metabolite used in urine drug tests to screen for marijuana use.
“In many cases,” he said, the positive test came “after a single acute dose, and in most cases, after chronic dosing for two weeks.” Typically positive tests would cease after a few days of the person stopping use, but some people were still testing positive for THC use a week later.
Terpenes—often pointed to by cannabis connoisseurs as responsible for modulating the experience of a particular strain or product—are a complicated matter that scientists are still sorting out, Vandry said. For example, he noted that famed cannabis researcher Ethan Russo promoted the notion “based on the idea of the entourage hypothesis,” which asserts that various chemicals in cannabis modulate the overall experience.
Today, “a lot of marketing and advertising in the cannabis industry will make claims that specific terpenes do or promote certain types of therapeutic or beneficial effects above and beyond cannabis itself,” Vandry explained. Sometimes that’s supported by evidence, while other times it’s not, he said.
For example, in an experiment Vandry and Russo collaborated on, subjects were given the terpene D-limonene along with 30 mg doses of pure, inhaled THC.
“As we added doses of limonene to it, we got dose-orderly reductions in subjective ratings of anxiety and paranoia and the subjective feeling that their heart was racing,” he said, “but the overall magnitude of the drug effect was unchanged, cognitive impairment was unchanged… It seems here that limonene has a very specific non-cannabinoid mechanism by which it can attenuate the anxiety or panic-inducing effects of high doses of THC.”
By contrast, similar testing showed little evidence for the claimed effects of another terpene, alpha-pinene, which the cannabis industry sometimes promotes as reducing anxiety, easing breathing and counteracting the memory-impairing effects of THC.
“We didn’t really see any effect there,” Vandry said. “In contrast to the D-limonene study, we really saw no significant effect of alpha-pinene addition to delta-9 THC…on subjective drug effects, memory [effects] of any sort or cardiovascular effects.”
Other issues the webinar touched on included psychosis and schizophrenia, differences in cannabis effects between male and female subjects as well as the need for more research and increased quality control around cannabis.
With regard to what some have claimed is a causal link between marijuana and schizophrenia, Vandry was skeptical, noting that although in recent years, “past-year cannabis use has doubled in the U.S., the rate of schizophrenia has remained absolutely stagnant.”
He acknowledged that there is “undoubtedly a strong correlation between heavy cannabis use and earlier onset of psychosis, and psychosis severity” but said “the causality on someone who would not otherwise develop psychosis is still questionable.”
Vandry also warned that cannabis use disorder is a very real public health issue, with cessation rates similar to other drugs of abuse, such as nicotine or alcohol. Further, there’s some evidence that “females tend to react to the drug differently.”
“They metabolize the drug differently, they progress more rapidly from first use to problematic use and are more treatment-resistant,” he explained, adding that female users also “tend to have greater withdrawal symptoms than men.”
He also cautioned against focusing on THC potency levels in marijuana products, saying that overall dose, not potency, is what matters.
“What we see is that people will adjust their use behavior based on the potency of the product,” the researcher said, explaining a concept known as self-titration. “If you gave someone five percent flower and 30 percent flower, your routine frequent daily user is going to smoke much more of the five percent to get to about the same dose.”
“I think it’s more challenging for people to titrate their use of a high-potency product, but it’s the dose, not the concentration of the product,” he said.
Effects can also vary by diet, especially when cannabis products are administered orally. For example, “cannabinoids taken with a high fat meal are absorbed much greater than if they’re taken on an empty stomach, which is the opposite of what is the case for most medications,” Vandry said.
Cannabinoids can also interact with drugs like alcohol or even caffeine.
The gaps between policy and scientific understanding underscores what Vandry said was a need for more investment in research, data collection and product testing and standardization.
“We need to do a better job in figuring out abuse liability across these different types of products and get regulation that makes sense, that’s product-specific and dose-specific and formulation- and route-specific,” he said. “We need better control on quality control in terms of retail products and understanding these minor cannabinoids and terpenes.”
“I kind of already said this,” Vandry concluded, but “I’d really like to see regulation not be on cannabis broadly, but on THC-dominant cannabis, CBD-dominant cannabis and other types of products, because the current policy really misses the point, where you have delta-8 on one end of the spectrum and delta-9 on the other.”
The goal, it said, is to “support advancements in breeding programs, enhance product quality control, and guide future research in cannabis sensory science.”
Amid an upswing in marijuana research in the post-prohibition era, researchers are still unlocking new secrets about the cannabis plant. Researchers earlier this year, for example, announced that they successfully identified a new cannabinoid—cannabielsoxa—produced by the marijuana plant as well as a number of other compounds “reported for the first time from the flowers of C. sativa.”
Among the findings were what the paper called a “massive” set of genes on one plant chromosome that involved about 60 megabases (Mb) and was associated specifically with THC-dominant cannabis strains.
The article said the results “offer valuable guidance for Cannabis breeding programs, enabling the use of precise genetic markers to select and refine promising Cannabis varieties.”
While research into marijuana has exploded in recent years as the result of more jurisdictions legalizing the drug for medical and adult use, it’s unclear how the Trump administration’s priorities will impact that trend.
Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
The U.S. Senate voted, 50-47, on July 22 to confirm President Donald Trump’s nomination of Terrance Cole to be the Drug Enforcement Administration (DEA) Administrator.
Cole, who just last year promoted an article claiming cannabis is linked to higher suicide risks for high schoolers, is now in the driver’s seat of the current cannabis rescheduling hearing process that’s been delayed for six months.
Under an order from DEA Chief Administrative Law Judge John J. Mulrooney II, Cole now has sole discretion on whether the hearing process, to debate the merits of a proposed rule to reclassify cannabis to Schedule III under the Controlled Substances Act, should resume.
Cole told U.S. senators during his April confirmation hearing that “it’ll be one of my first priorities” to review where the DEA is in the administrative process to reschedule cannabis upon being confirmed.
However, Cole provided no promises on the Schedule III proposal that was recommended by former President Joe Biden’s U.S. Department of Health and Human Services and published in the Federal Register after former Attorney General Merrick Garland signed off on a notice of proposed rulemaking. Biden’s DEA never backed the proposal.
Cole told members of the Senate Judiciary Committee that he’d give “the matter careful consideration after consulting with appropriate personnel within the Drug Enforcement Administration, familiarizing myself with the current status of the regulatory process, and reviewing all relevant information.”
Here’s how cannabis industry stakeholders reacted to Cole’s July 22 confirmation vote.
Aaron Smith, Co-Founder and CEO of the National Cannabis Industry Association – (In an Open Letter to Terrance Cole)
“Last year, we were honored to be designated by the DEA as one of the select participants in the agency’s public hearing process for the Notice of Proposed Rulemaking (NPRM) to move cannabis from Schedule I to Schedule III under the Controlled Substances Act.
“NCIA continues to believe that marijuana should not be subject to the Controlled Substances Act (CSA); rather, that marijuana products should be regulated under uniform product safety standards that apply equally to all licensed marijuana businesses and protect consumers across the country, developed under new federal law that recognizes that cannabinoid products cannot be governed under the same regulatory pathways that currently apply to pharmaceutical drugs, food, dietary supplements, alcohol, or tobacco.
“However, our association recognizes that the DEA has only been considering the rescheduling of marijuana. We are eager and ready to work with the DEA and Trump administration to, as you said during your confirmation hearing, ‘listen to the experts’ and ‘follow the science,’ which we are confident will lead to a change in marijuana’s status federally. The rescheduling process under the previous administration was unnecessarily protracted and fraught by allegations of malfeasance within DEA and we look forward to your renewed leadership to expedite this process and fulfill President Trump’s campaign promise to ‘unlock the medical uses of marijuana to a Schedule III drug’ and ultimately ‘implement smart regulations, while providing access for adults, to safe, tested product.’
“As such, we strongly encourage your office to continue advancing the cannabis rescheduling process in a timely and transparent manner. The recent recommendation by the Department of Health and Human Services to reclassify cannabis to Schedule III is grounded in the scientific, medical, and legal standards required by 21 U.S.C. § 811. Rescheduling would help eliminate unnecessary barriers to research, reduce burdens on legitimate businesses operating under state law, and bring federal policy more in line with overwhelming public opinion and decades of state-level reform.
“As DEA considers next steps, we respectfully urge your administration to recognize the importance of collaboration with stakeholders who can offer real-world insights into the public health, enforcement, and operational impacts of federal cannabis policy. NCIA and our members welcome any opportunity to be constructive partners in that effort.” – Aaron Smith
Kyle Sherman, Founder & CEO of Flowhub
“We’re watching the appointment of DEA Administrator Terrence Cole closely. While his background overseeing Virginia’s [Public Safety and Homeland Security] may seem encouraging, questions remain about the political motivations behind his selection. President Trump made clear just last week that this was a Governor Glenn Youngkin-backed appointment and publicly stated he would hold Youngkin accountable if Cole does not deliver. Youngkin, notably, has not been a supporter of the cannabis industry.
“Fortunately, Executive Order 14215, issued by President Trump in February 2025, ensures accountability at the federal level. Section 7 of that order explicitly prohibits agencies and their employees from issuing legal guidance or interpretations that deviate from those of the President and Attorney General. This safeguard exists to prevent political freelancing and keep federal policy aligned with the administration’s commitments.
“If Administrator Cole honors this Executive Order, the will of the public, the President’s promise to unlock safe access to medical cannabis through the reclassification of cannabis to a Schedule III drug, and his own promise to ‘listen to the experts’ and ‘follow the science’ as he testified during his nomination hearing, we’re hopeful he can be an agent of long overdue reform. But we’ll be watching closely.” – Kyle Sherman
Anthony Coniglio, CEO of NewLake Capital Partners
“The conversation around cannabis policy is again clouded by speculation. What we know is limited—but meaningful. Mr. Cole has said cannabis rescheduling will be ‘one of [his] first priorities,’ and that he will rely on science, expert consultation and the framework of the Controlled Substances Act to guide his decision.
“That’s not a political promise—it’s a procedural one. And in today’s regulatory climate, that matters.
“More telling is what Mr. Cole has made unequivocally clear: His focus will be on dismantling fentanyl networks and transnational criminal organizations. That aligns with the DEA’s 2025 National Drug Threat Assessment, which notably downplays cannabis and instead emphasizes synthetic drugs and the organized crime groups behind them. In that context, rescheduling cannabis isn’t just a policy adjustment—it’s a way for the DEA to better distinguish between bad actors and law-abiding, compliance-driven operators.
“Whether Mr. Cole will be a steward of regulatory modernization or a placeholder for the status quo remains to be seen. But the next 100 days offer a chance to turn a long-overdue page. If he leads with science and enforcement clarity—not outdated fears—this could be the start of a smarter, more modern drug policy.” –Anthony Coniglio
Terry Mendez, CEO of Safe Harbor Financial
“The Senate’s advancement of Terrance Cole’s nomination as DEA Administrator is a consequential development for the cannabis industry. With the rescheduling of cannabis under federal law stalled, the incoming DEA leadership will play a defining role in whether that reform moves forward—or remains mired in uncertainty.
“While we welcome Terry Cole’s stated commitment to reviewing the rescheduling proposal, the industry needs more than vague assurances. We need regulatory clarity, fairness, and above all, urgency. The decisions ahead will directly impact the viability of thousands of licensed cannabis operators and the broader financial infrastructure supporting them.
“However, even in the most optimistic scenario where cannabis is rescheduled from Schedule I to Schedule III, we must be clear-eyed about the limitations of that change. Rescheduling does not equate to legalization. It will not eliminate the burdensome compliance regimes that currently deter most large financial institutions from entering the market. Anti-Money Laundering and Bank Secrecy Act requirements will still apply, and the cannabis industry will remain federally criminalized in practice—if not in label.
“Contrary to popular belief, banking services for cannabis businesses are not unavailable today—but they are fragmented, costly, and carried disproportionately by smaller, specialized institutions like Safe Harbor. Rescheduling might offer incremental improvements, but absent updated FinCEN guidance and comprehensive congressional action like the SAFER Banking Act, the financial exclusion of cannabis operators will continue.
“This is a moment to double down on the push for safe banking, tax equity and transparent regulatory treatment. At Safe Harbor, we are committed to ensuring that cannabis businesses—large and small—have access to the financial tools they need to thrive. We urge the new DEA leadership to move swiftly, and Congress to act decisively, so this industry can finally be treated as what it is: legal, regulated, and essential to communities across America.” -Terry Mendez
The Wisdom of Oz: Green Grass, White Powder & Black Sabbath
by Chris Simunek
When you look back at the history of rock’n’roll, it is almost exclusively populated by people from two categories:
Those Who Got Fucked Up, and
Those Who Got Really Fucked Up.
For the latter part of the ’70s and all of the ’80s, Ozzy Osbourne was the Chairman of the Board for category number two. I learned of his legend the way most kids my age did—from pimple-faced geeks in denim jackets with their favorite album painted on the back. The story was always told with the appropriate reverence: He invented heavy metal, he drank a lot, he did a lot of drugs, made some great albums, was kicked out of Black Sabbath for being a loser and then he went solo, bit the head off a bird, bit the head off a bat, pissed on the Alamo, had a guitarist that died in a freak plane crash, went through a period where he looked and dressed a little like Liz Tay lor, and now he is sober and quite successful, albeit a bit shell-shocked.
On the heels of his successful Ozzfest tour, a traveling roadshow that has packaged the likes of Marilyn Manson, Tool, Type-0 Negative and Pantera, Ozzy stunned his fans with the announcement of his reunion with the other members of the original Black Sabbath lineup: guitarist Tony Iommi, bassist Geezer Butler and drummer Bill Ward. It’s something they’d been threatening to do for a decade, but the authentic Sabbath hadn’t played together (aside from a Live Aid appearance) since 1979. On December 5, 1997, they played in their hometown of Birmingham, England, a city of industry that makes Pittsburgh look like Paris, and recorded the show for their new live double-disc set, Reunion.
THE FOLLOWING INTERVIEW GOES TO “II”
Ozzy and Tony Iommi were in New York recently for a Letterman appearance and a meet-and-greet at the new Virgin Megastore in Union Square. When their people contacted HIGH TIMES about a possible interview, I thought it was a prank. I imagined some high school enemy of mine at the other end of the line— “Yeah man, Ozzy wants to hang out and do bong hits with you guys and then Alice Cooper’s gonna drop by with a couple peyote buttons…” Verifying my sources, I found it was true, Ozzy did have something to say to his bonghitting brethren, and was waiting for us in a suite at the St. Regis. Not wanting to undertake such an important mission alone, I invited Rob Braswell, HIGH TIMES’ production director/token metalhead, to join me. What Ozzy and Tony had to say to us we weren’t sure, but we weren’t going to pass up a chance to sit and giggle sycophantically at the feet of our gods.
We arrived early and had a few Berliner weissbiers at the Old King Cole bar to calm our nerves. As we discussed what questions we should ask our favorite air-guitar jamming partners, we both agreed this wasn’t a music interview. If you want to know what Ozzy thinks of the new album or where Tony nicked the riff to “Iron Man,” go read Guitar Player. We wanted tales of rock n roll debauchery, nothing more, nothing less. Ozzy’s people called the bar and informed us that the King of Doom was ready to see us. in the lobby, we were met by a publicist who told us that Ozzy was sick of talking about his indiscretions at American national landmarks and his past cruelties to the animal kingdom. It was implied that a good interviewer might want to steer clear of such subjects.
“Don’t worry,” I told her. ”I just want to talk about drugs.”
Ozzy and Tony were finishing up a previous interview when we walked into their suite. They were both dressed in classic black with large crosses dangling from their necks, sunglasses covering their eyes.
“Are you rolling yet?” Ozzy cracked as we entered.
When you meet Ozzy, it’s kind of like shaking the hand of a man who just came out of a 30-year panic attack. His hands tremble, his voice stutters, but imagine how you’d feel if you’d spent over a quarter-century in a drunken stupor, screaming your ass off in front of a wall of deafening amplifiers, tweaked on enough central-nervous-system stimulants to jump-start Walt Disney’s cryogenically frozen heart. Having heard that Ozzy was completely sober, I asked him if his rolling remark was just a joke.
“Why, you got any?” he inquired.
“Of course,” I said. “You think I’m going to come to this interview emptyhanded?”
“Is there any grown in New York?” he asked.
“Yeah, sure,” I said.
“What I used to do was nip every other leaf so it would grow out instead of up.”
I smiled. Ozzy had given us a genuine grow tip.
“What did you do?” I asked. “Grow it outdoors?”
“Yeah,” Ozzy said with a grin. “But then I got paranoid.”
The word hung there, begging a response.
“Yeah… to coin a phrase. So I’ve got to ask you about Sweet Leaf. Where did that come from?”
“Well, what do you think?” Ozzy laughed. “We used to smoke pounds of the shit, man. We used to buy it by the fuckin’ sackful. We used to be so fucked up all the time. Wake up in the morning, start the day with a spliff and go to bed with it. Yeah, it started to get… I started to get the heebee-jeebees. I was mixing all kinds of other chemicals. Booze, coke, pills…”
“Do you see a difference between pot and other chemicals?”
“Absolutely,” he said, waving his cigarette. “This, for instance, tobacco. I couldn’t smoke as many joints a day as I can this fuckin’ stuff. Gotta legalize pot. I’m all for the legalization of pot, decriminalize it. I don’t smoke it myself, but if anybody wants to smoke it, fine. I got busted for it. We all did.”
“Speaking of busts, what was it like for Black Sabbath to go through Customs in the ’70s?”
“Pretty scary.”
“Did you guys ever have to drop trou?”
“Oh yeah. I remember one time we went from Detroit to Canada through the tunnel. I grabbed one of the guys and asked him, ‘Have we done all the drugs?’ Then I go through my bags and empty them again and, remember them pipes you could get with a fish pump? You got like a fish-tank pump and all these wires and you put the pot in and you just suck on the pipe. They found that.” Ozzy hit his cigarette and chuckled. “Big rubber gloves, the whole nine yards. For fuckin’ smoking pot, man.”
“Do you get more paranoid in the States?”
“I just get paranoid,” he said. “When I do coke I’m like Mr. Paranoia. I’m fucking scared shitless. When you combine it with Demerol and opiates you get real fucked up, you know? You think to get normal, you have to get high. Anything in moderation, but with cocaine I couldn’t.”
“It makes for good VHi documentaries though,” I commented. “You guys in the ’70s had a rep for taking the most amount of time to record records.”
“We were fucked up!” Ozzy laughed at the obvious.
“Which record took the longest?”
“Oh, I don’t know,” Tony answered, not as impressed by Sabbath’s more dubious accomplishments as I was.
“We went to Canada one time, uh…” Ozzy looked at Tony to help him pull the memory out.
“Never Say Die.”
“Never Say Die took fuckin’ forever,” Ozzy said, and the two of them giggled like kids remembering a particularly naughty Halloween prank. “We got this guy coming around giving us bags of cocaine every fuckin’ Wednesday and we’d be like—” Ozzy clenched his face like a coke-freak frozen in action.
“Oh yeah,” Tony said. “When we started out the albums were quick and then…” He shrugged his shoulders, as if there was nothing that could be done about it now.
“With coke,” I wondered, “wouldn’t you record the album fast?”
“You’d do it and then you’d forget what you were doing!” Ozzy said laughing. “We couldn’t turn the fucking tape machine on! We’d turn like pause’ on instead of play/record,’ you know. We’d be playing for fuckin’ twenty-four hours.”
“These neat little bags,” Tony said, reminiscing, “Just chop us another line out! Get another can of beer out the fridge! Roll another joint!” Ozzy shouted. “We used to smoke blocks of hash. Big fuckin’… we used to buy hash by the pound.”
“And coke,” said Tony. “We used to buy these sealed bottles of coke.”
“Government-sealed,” Ozzy added. “We rented this house in Bel Air and we just had these fucking packages up to here—” With his hands Ozzy indicated a pile about the size of a Volkswagen. “It would come in like big gallon-bottles with a spoon on it, covered with a seal of wax. This coke was the best coke that I’ve ever had. I’m lying by the pool one day and I met this guy and I ask him You want to do some coke?’ He goes, No no no.’ I’m whacking this stuff up my nose, it’s a brilliant sunny day, and this guy’s sitting there with one of those reflectors under his chin getting a suntan. I say, What do you do?’ He says, I work for the government.’ Uh… what do you do with the government?’ I work for the drug squad.’ I sez, You’re fucking joking. He shows me his badge. I fuckin’ flipped. I was fuckin’—” Ozzy slammed his fist in his chest like a raging heartbeat. “Flames were coming out of my fingers, man. He says, Oh you’re all right, I’m the guy that got you the coke.’
“We all got fucked up but me and Bill went fuckin’ a little bit further,” Ozzy continued. “Bill ended up in a psychiatric fuckin place. Bill’s antidrug, antidrink, antieverything now. He don’t mince his fucking words either, you know.
With the coke and all these chemicals. 1 got a chemical imbalance in my brain. I’d become really shaky. I have to take Prozac and various medications just to stabilize me.”
“So you never drink, or every once in a while you’ll have something?”
“I don’t drink right now’. Every once in a while is like… I’ve done OK so far, you know’.
I’m not going to say Til never drink again.’ I don’t know. When I’m doing a show’ and I can smell that wonger out in the front, it does tempt me. One thing about the cocaine, though. It used to isolate you and you used to stay in your room paranoid. You buy a bag of white powder and the paranoia soon follows.”
“I’ll never do it again,” said Tony, remembering a promise he once made.
“And when you hear those birds going in the morning tweet-tweet you want to get a fucking machine gun and shoot every bird in sight.
When the day breaks it’s horrible. And what do you do when you wake up? Snnnnnnmmmmfff. Like a fiend, you know.”
“Why is it that so many rock stars crack up?” I asked. “Isn’t it supposed to be the best job in the world?”
“What other job can you imagine where the more fucked up you turn up, the better people think you’re gonna be? Oh fuckin’ Tony’s stoned or Ozzy’s stoned or Bill’s stoned… it’s going to be good fun tonight.’ Too much of anything, eventually you pay a price. If you play now, you pay later, I don’t give a fuck what it is.”
“Is it rough to be sober these days?” I asked, sensing a bit of regret in his voice.
“It sucks,” he replied bluntly. “I don’t like being sober, but say you chopped some lines, I’d go, ’Yeah, I’ll go for it.’ By twelve o’clock I’d be hanging off the fucking building screaming with a bottle of vodka in my hand. Once I start I can’t fucking stop. I gotta go all the way, you know.”
“So what do you do now to fill the gap?”
“Play with my dick,” Ozzy answered with a laugh. “In the ’70s there was a big period of time when I used to drink cheap wine and do ludes. I’d be like fucking jelly and the audience would be like a pond, a fucking oil slick. They were sweaty fuckin’ downed-out fuckin’…” Ozzy trailed off, as if he could still see that placid sea and then asked, “Did you ever try the original Quaaludes?”
The cooler half of Black Sabbath trained their eyes on me and for a moment I felt like a pink, newborn fetus. “No,” I answered with shame. “That’s a little bit before my time.”
“They were fucking wonderful, weren’t they?” Ozzy said and then looked to Tony for confirmation. “I could still get them,” Ozzy offered. “I know somebody who froze ten thousand.”
“Froze them?” I pictured a skinny hipster with sunken cheeks stocking up on 714s so that when the world’s methaqualone supply ran out, he could rise from his bunker and be the Lord of the Lucies.
I was running out of questions and would have to wing a few.
“We were wondering like…” I combed my beery skull for a relevant topic. “Well, since Meatloaf came out with Bat Out of Hell II and Frampton came out with Frampton Comes Alive II, would you ever come out with Volume IV, II?”
“No,” Tony answered as if I should know an artist of his caliber doesn’t repeat himself like that.
“I don’t think so, no,” Ozzy said, pondering the question before a grin split across his face and he let out another tremolo laugh. ” Volume IVII, yeah. Volume IV1/2 * 2… he-he-he.
“We had a question about like, uh… heavymetal fashion in the ’80s.”
“Oh, don’t,” Ozzy started. It was obviously a sore subject.
“What was up with that?”
“I look back at some of those things and I was drinking an enormous amount of booze. Every day I would drink four bottles of Hennessy, a case of Budweiser and as much fucking dope as I could get down my fucking face. As much as I could. I was overdosing on a daily basis.” Ozzy laughed again at the thought of it. Unlike other sober-rockers, he still gets a kick out of his past.
“That’s where the funny clothes came from?” I asked.
“I think that’s where the funny everything came from,” he answered. “We all thought we looked cool. Now we look at ourselves—gay wasn’t even the word. Gay people used to come to us and say, What are you fucking doing, man?’ ” Ozzy pondered for a moment and said, “It’s all part of the crazy world of rock’n’roll.”
I made the mistake of mentioning the time Ozzy put on a dress and redecorated the Alamo and he visibly cringed. It was like asking Achilles to repeat the story about the time he fucked up his heel. He was somewhat appeased when I informed him that this incident was now a highlight of the Alamo tour. At first he didn’t believe me, but I swore to him that a Texan friend had just seen it.
“They should put it in the Guinness Book of World Records.” offered Tony.
“Your own indelible mark upon American history,” I said and a proud, impish smile spread across Ozzy’s face. Our time was running out, so we asked Ozzy to autograph a few records. I handed him my beaten copy of Paranoid. With a quivery hand Ozzy scrawled “Get Stoned” across the gatefold and then signed his name. It was advice from an expert.
Back down at the Old King Cole, Rob and I felt invigorated, like we’d just been to the Rock’n’Roll Doctor and he’d given us a shot of Vitamin Cool.
“He was just like I imagined,” Rob cooed.
“Yeah,” I said, my eyes full of butterflies. That a guy could go through what Ozzy did and still be on top was more than luck, it was damn close to a miracle. When the going got tough, he dressed up in women’s clothing and pissed on national landmarks.
I decided from that point on to try and be more like Ozzy.
He has a message for people like me: If you want a yellow brick road to follow, you have to pause sometimes and paint the stones yourself.
Several reforms to North Dakota’s medical cannabis law are set to take effect August 1, including the sale of low-dose THC edibles and extended timeframes for the validity of medical cannabis cards, the North Dakota Monitor reports.
Edibles now allowed under the medical cannabis program may contain no more than 5 milligrams of THC and no more than 50 milligrams per package. The products can be in the form of a lozenge or a square shape; other foods or beverages are not allowed.
Jake Mittelsteadt, director of retail operations for Pure Dakota Health, told the Monitor that allowing edibles could be a game changer for patients.
“Since day one of this program, the amount of people that joined the program, that come to the state, everybody, especially in the older demographics, their priorities have always been gummies and edibles.” — Mittelsteadt to the Monitor
Under the reforms, patients will also be able to qualify for the program via telehalth rather than just using telehealth services to renew their medical cannabis cards. Medical cannabis cards are also now valid for two years instead of one.
TG joined Ganjapreneur in 2014 as a news writer and began hosting the Ganjapreneur podcast in 2016. He is based in upstate New York, where he also teaches media studies at a local university.
More by TG Branfalt
